191 related articles for article (PubMed ID: 35977549)
1. Exploring the Role of Sodium-Glucose Cotransporter as a New Target for Cancer Therapy.
Bardaweel S; Issa A
J Pharm Pharm Sci; 2022; 25():253-265. PubMed ID: 35977549
[TBL] [Abstract][Full Text] [Related]
2. Sodium-glucose co-transporter-2 (SGLT-2) inhibition reduces glucose uptake to induce breast cancer cell growth arrest through AMPK/mTOR pathway.
Zhou J; Zhu J; Yu SJ; Ma HL; Chen J; Ding XF; Chen G; Liang Y; Zhang Q
Biomed Pharmacother; 2020 Dec; 132():110821. PubMed ID: 33068934
[TBL] [Abstract][Full Text] [Related]
3. Model-Based Evaluation of Proximal Sodium Reabsorption Through SGLT2 in Health and Diabetes and the Effect of Inhibition With Canagliflozin.
Brady JA; Hallow KM
J Clin Pharmacol; 2018 Mar; 58(3):377-385. PubMed ID: 29144539
[TBL] [Abstract][Full Text] [Related]
4. SGLT2 inhibitor ipragliflozin attenuates breast cancer cell proliferation.
Komatsu S; Nomiyama T; Numata T; Kawanami T; Hamaguchi Y; Iwaya C; Horikawa T; Fujimura-Tanaka Y; Hamanoue N; Motonaga R; Tanabe M; Inoue R; Yanase T; Kawanami D
Endocr J; 2020 Jan; 67(1):99-106. PubMed ID: 31776304
[TBL] [Abstract][Full Text] [Related]
5. Susceptibility to serious skin and subcutaneous tissue disorders and skin tissue distribution of sodium-dependent glucose co-transporter type 2 (SGLT2) inhibitors.
Sakaeda T; Kobuchi S; Yoshioka R; Haruna M; Takahata N; Ito Y; Sugano A; Fukuzawa K; Hayase T; Hayakawa T; Nakayama H; Takaoka Y; Tohkin M
Int J Med Sci; 2018; 15(9):937-943. PubMed ID: 30008607
[No Abstract] [Full Text] [Related]
6. High Basolateral Glucose Increases Sodium-Glucose Cotransporter 2 and Reduces Sirtuin-1 in Renal Tubules through Glucose Transporter-2 Detection.
Umino H; Hasegawa K; Minakuchi H; Muraoka H; Kawaguchi T; Kanda T; Tokuyama H; Wakino S; Itoh H
Sci Rep; 2018 May; 8(1):6791. PubMed ID: 29717156
[TBL] [Abstract][Full Text] [Related]
7. Impact of sodium-glucose cotransporter 2 inhibitors on blood pressure.
Reed JW
Vasc Health Risk Manag; 2016; 12():393-405. PubMed ID: 27822054
[TBL] [Abstract][Full Text] [Related]
8. SGLT1 in pancreatic α cells regulates glucagon secretion in mice, possibly explaining the distinct effects of SGLT2 inhibitors on plasma glucagon levels.
Suga T; Kikuchi O; Kobayashi M; Matsui S; Yokota-Hashimoto H; Wada E; Kohno D; Sasaki T; Takeuchi K; Kakizaki S; Yamada M; Kitamura T
Mol Metab; 2019 Jan; 19():1-12. PubMed ID: 30416006
[TBL] [Abstract][Full Text] [Related]
9. Canagliflozin Inhibits Glioblastoma Growth and Proliferation by Activating AMPK.
Shoda K; Tsuji S; Nakamura S; Egashira Y; Enomoto Y; Nakayama N; Shimazawa M; Iwama T; Hara H
Cell Mol Neurobiol; 2023 Mar; 43(2):879-892. PubMed ID: 35435536
[TBL] [Abstract][Full Text] [Related]
10. Sodium glucose cotransporter 2 inhibitor canagliflozin attenuates liver cancer cell growth and angiogenic activity by inhibiting glucose uptake.
Kaji K; Nishimura N; Seki K; Sato S; Saikawa S; Nakanishi K; Furukawa M; Kawaratani H; Kitade M; Moriya K; Namisaki T; Yoshiji H
Int J Cancer; 2018 Apr; 142(8):1712-1722. PubMed ID: 29205334
[TBL] [Abstract][Full Text] [Related]
11. Sodium glucose co-transporter 2 inhibitors: a novel approach to the management of type 2 diabetes mellitus.
Davis CS; Fleming JW; Warrington LE
J Am Assoc Nurse Pract; 2014 Jul; 26(7):356-63. PubMed ID: 24895099
[TBL] [Abstract][Full Text] [Related]
12. Feasibility Study to Assess Canagliflozin Distribution and Sodium-Glucose Co-Transporter 2 Occupancy Using [
van der Hoek S; Willemsen ATM; Visser T; Heeres A; Mulder DJ; Bokkers RPH; Slart RHJA; Elsinga PH; Heerspink HJL; Stevens J
Clin Pharmacol Ther; 2023 Jun; 113(6):1295-1303. PubMed ID: 36897753
[TBL] [Abstract][Full Text] [Related]
13. Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus.
Scheen AJ
Drugs; 2015 Jan; 75(1):33-59. PubMed ID: 25488697
[TBL] [Abstract][Full Text] [Related]
14. Effects of Sodium/Glucose Cotransporter 2 (SGLT2) Inhibitors and Combined SGLT1/2 Inhibitors on Cardiovascular, Metabolic, Renal, and Safety Outcomes in Patients with Diabetes: A Network Meta-Analysis of 111 Randomized Controlled Trials.
Teo YN; Ting AZH; Teo YH; Chong EY; Tan JTA; Syn NL; Chia AZQ; Ong HT; Cheong AJY; Li TY; Poh KK; Yeo TC; Chan MY; Wong RCC; Chai P; Sia CH
Am J Cardiovasc Drugs; 2022 May; 22(3):299-323. PubMed ID: 35316484
[TBL] [Abstract][Full Text] [Related]
15. Characterization and comparison of sodium-glucose cotransporter 2 inhibitors in pharmacokinetics, pharmacodynamics, and pharmacologic effects.
Tahara A; Takasu T; Yokono M; Imamura M; Kurosaki E
J Pharmacol Sci; 2016 Mar; 130(3):159-69. PubMed ID: 26970780
[TBL] [Abstract][Full Text] [Related]
16. Comparing and Contrasting the Effects of the SGLT Inhibitors Canagliflozin and Empagliflozin on the Progression of Retinopathy.
Herat LY; Matthews JR; Rakoczy EP; Schlaich MP; Matthews VB
Front Biosci (Landmark Ed); 2023 Apr; 28(4):83. PubMed ID: 37114550
[TBL] [Abstract][Full Text] [Related]
17. SGLT2 inhibitor promotes mitochondrial dysfunction and ER-phagy in colorectal cancer cells.
Anastasio C; Donisi I; Del Vecchio V; Colloca A; Mele L; Sardu C; Marfella R; Balestrieri ML; D'Onofrio N
Cell Mol Biol Lett; 2024 May; 29(1):80. PubMed ID: 38811901
[TBL] [Abstract][Full Text] [Related]
18. Ipragliflozin and other sodium-glucose cotransporter-2 (SGLT2) inhibitors in the treatment of type 2 diabetes: preclinical and clinical data.
Kurosaki E; Ogasawara H
Pharmacol Ther; 2013 Jul; 139(1):51-9. PubMed ID: 23563279
[TBL] [Abstract][Full Text] [Related]
19. Renal and Cardiac Implications of Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors: The State of the Science.
Cruz JE; Ahuja T; Bridgeman MB
Ann Pharmacother; 2018 Dec; 52(12):1238-1249. PubMed ID: 29911393
[TBL] [Abstract][Full Text] [Related]
20. Perturbations of cancer cell metabolism by the antidiabetic drug canagliflozin.
Papadopoli D; Uchenunu O; Palia R; Chekkal N; Hulea L; Topisirovic I; Pollak M; St-Pierre J
Neoplasia; 2021 Apr; 23(4):391-399. PubMed ID: 33784591
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
